Key Takeaways Aficamten outperformed metoprolol on all key endpoints in the MAPLE-HCM phase III trial.Additional data showed aficamten improved heart structure, function, and reduced atrial fibrillation.FDA extended aficamten's target action date to Dec. 26, 2025, after requesting a REMS submissionIt has been a roller coaster ride for Cytokinetics, Inc. (CYTK) so far in 2025.While the delay in FDA approval of its lead candidate aficamten for the treatment of patients with obstructive hypertrophic cardiomyop ...